Erdafitinib/Bocco belongs to the first generation of targeted drugs

Erdafitinib (Erdafitinib) is an oral small molecule FGFR (fibroblast growth factor receptor) inhibitor, which is a new generation of targeted therapy drugs that has developed rapidly in recent years. Traditional targeted drugs mostly focus on the EGFR, ALK or VEGFR pathways, while erdafitinib targets the FGFR1-4 pathway. Such mutations or fusions play an important role in some tumor patients. Therefore, erdafitinib is usually classified as a targeted drug with new targets. From the perspective of development time and clinical application, it can be considered an innovative targeted drug after the third generation, representing a trend in precision cancer medicine.

Compared with the first or second generation targeted drugs, the biggest feature of erdafitinib is its unique target, which fills the gap in the treatment of tumors related to FGFR mutation. In the past, such patients often lacked effective molecular targeted treatments and could only rely on chemotherapy or immunotherapy. The emergence of erdafitinib provides a new option for these patients. According to overseas research data, mutations or fusions of FGFR2 and FGFR3 are relatively common in some malignant tumors such as bladder cancer and cholangiocarcinoma, which also provides a theoretical basis for the application of erdafitinib.

In addition, the development and approval of erdafitinib also demonstrates the development path of targeted drug development from a single target to precise inhibition of multiple pathways. Compared with early targeted drugs, it not only directly blocks the signal transduction of tumor cells through FGFR inhibition, but also affects the angiogenesis and microenvironment of the tumor, thereby enhancing the therapeutic effect.

Therefore, from the perspective of drug classification and development context, erdafitinib belongs to a new generation of innovative targeted drugs. Its emergence marks the expansion of targeted therapy from traditional common mutations to more rare mutations, which is of great significance in promoting the development of precision medicine.

Reference materials：https://www.balversa.com/